Skip Navigation
Skip to contents

대한신장학회


간행물 검색

현재 페이지 경로
  • HOME
  • 간행물
  • 간행물 검색
논문분류 춘계학술대회 초록집
제목 Effects of Spironolactone in Combination with ACE Inhibitor or Angiotensin Receptor Blockers in Aldosterone Escape and Non-escape Group of Patients with Proteinuria
저자 Ha Yeon Kim, Chan Young Oak, Yong Un Kang, Chang Seong Kim, Joon Seok Choi, Eun Hui Bae, Seong Kwon Ma, Soo Wan Kim
출판정보 2013; 2013(1):
키워드 Spironolactone, 단백뇨/ Spironolactone, Aldosterone escape, Proteinuria
초록 Background: Conventional blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) does not adequately protect against target organ damage. Thus, add-on aldosterone blockade therapy may constitute a therapeutic strategy for progressive kidney disease. The present study was aimed to investigate whether add-on aldosterone blockade therapy has beneficial antiproteinuric effects in aldosterone escape and non-escape group in association with changes of vitamin D level. Methods: In this prospective intervention trial, we studied the effects of spironolactone (25 mg/day) in 211 patients who showed persistent proteinuria after ACE inhibitor or ARB medications for more than 3 months. Plasma aldosterone, renin, potassium, estimated GFR (eGFR) and urine protein to creatinine ratio were determined at baseline and 6 months after spironolactone add-on treatment. Patients were divided according to their aldoterone level during ACE inhibitor or ARB treatment in an escape group (plasma aldosterone >80 pg/ml, n=68, 32.2%) and a non-escape group (n=143, 67.8%). Results: Plasma aldosterone level was increased by 86.3% (77.90 to 145.19 pg/ml) and plasma renin activity also increased by 18.9% (6.18 to 7.35 ng/ml/hr) in both escape and non-escape group after spironolactone treatment. By using paried T-test, there was a tendency toward a decrease in urine protein to creatinine ratio in both groups (1.148±1.080 to 1.073±1.211, p=0.703 in aldosterone escape group, 1.86±2.508 to 1.41±1.251, p=0.175 in non-escape group). There was significant increase of plasma 25 OH vitamin D level after spironolactone treatment (12.27±5.883 to 14.69±4.361, p=0.006 in aldosterone escape group, 12.02±5.435 to 14.79±6.452, p<0.001 in non-escape group). Serum potassium has increased significantly (4.571±0.498 to 4.962±0.704, p<0.001 in aldosterone escape group, 4.51±0.606 to 4.82±0.844, p<0.001 in non-escape group) and hyperkalemia (K >5.5mEq/L) was developed in 29 of the 130 patient (13.6%). Furthermore, it seems like that antiproteinuria effect was different according to eGFR (1.489±1.053 to 1.567±1.360, p=0.681 in group with eGFR <60 mL/min/1,73m2, 1.353±1.457 to 0.959±1.102, p=0.277 in group with eGFR >60 mL/min/1,73m2). Conclusions: Adding spironolactone treatment seems to decrease the proteinuria in both aldosterone escape and non-escape group in association with the increase of vitamin D level .
원문(PDF) PDF 원문보기
위로가기